PIK3CA D350G

CI-VAR-00000480Explore in graph →NP_006209.2:p.Asp350GlyNM_006218.2:c.1049A>GClinVar 521363 CIViC 1653 rs1553821144

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
PIK3CA D350G	Vemurafenib	Predictive	D	Supports Resistance	2	accepted	EID4784 An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably o… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
521363	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Inborn genetic diseases; PIK3CA related overgrowth syndrome; Melanoma; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype	germline/somatic	4	Dec 11, 2024	clinvar